IP Verse

Compositions And Methods For Lowering Triglycerides Without Raising Ldl-C Levels In A Subject On Concomitant Statin Therapy - EP3318255

The patent EP3318255 was granted to Amarin Pharmaceuticals Ireland on Mar 10, 2021. The application was originally filed on Jun 15, 2010 under application number EP17187534A. The patent is currently recorded with a legal status of "Revoked".

EP3318255

AMARIN PHARMACEUTICALS IRELAND
Application Number
EP17187534A
Filing Date
Jun 15, 2010
Status
Revoked
Oct 21, 2022
Grant Date
Mar 10, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEDec 10, 2021ELKINGTON AND FIFEADMISSIBLE
HOFFMANN EITLEDec 8, 2021HOFFMANN EITLEADMISSIBLE
ELKINGTON AND FIFENov 24, 2021ELKINGTON AND FIFEADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONUS20071191467
OPPOSITIONUS2007191467
OPPOSITIONWO0044361
OPPOSITIONWO2008045465
SEARCHUS2007191467
SEARCHWO0044361
SEARCHWO2008045465

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "History of Changes for Study: NCT01492361 A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)", ClinicalTrials.gov archive, (20120316), pages 1 - 17, XP055844076-
OPPOSITION- C. VON SCHACKY, "A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels", Vascular Health and Risk Management, (20060000), vol. 2, no. 3, pages 251 - 262, XP002578779-
OPPOSITION- Haney E. M., Huffman L.H., Bougatsos C., "Appendix 2. Units of Measure Conversion Formulas", Screening for Lipid Disorders in Children and Adolescents, Rockville : Agency for Healthcare Research and Quality (US, (20070101), XP055911409-
OPPOSITION- VON SCHACKY CLEMENS, "A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.", VASCULAR HEALTH AND RISK MANAGEMENT, DOVE MEDICAL PRESS LTD.,, NZ, NZ , (20060101), vol. 2, no. 3, ISSN 1176-6344, pages 251 - 262, XP002578779-
OPPOSITION- RAMBJOR G. S., ET AL., "EICOSAPENTAENOIC ACID IS PRIMARILY RESPONSIBLE FOR HYPOTRIGLYCERIDEMIC EFFECT OF FISH OIL IN HUMANS.", Lipids, Springer, DE, DE , (19960101), vol. 31., no. 03, SUPPL., doi:10.1007/BF02637050, ISSN 0024-4201, pages S45 - S49., XP000614874
OPPOSITION- RAMBJOR G S et al., "EICOSAPENTAENOIC ACID IS PRIMARILY RESPONSIBLE FOR HYPOTRIGLYCERIDEMIC EFFECT OF FISH OIL IN HUMANS", LIPIDS, US, (19960101), vol. 31, no. 3, ISSN 0024-4201, pages S45 - S49, XP000614874
OPPOSITION- RAMBJOR G S et al., "EICOSAPENTAENOIC ACID IS PRIMARILY RESPONSIBLE FOR HYPOTRIGLYCERIDEMIC EFFECT OF FISH OIL IN HUMANS", LIPIDS, US, (19960101), vol. 31, no. 3, ISSN 0024-4201, XP000614874
OPPOSITION- NAKAMURA N et al., "Joint affects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, SPRINGER, BERLIN, DE, (19990301), vol. 29, no. 1, ISSN 0940-5437, pages 22 - 25, XP002558875
OPPOSITION- NAKAMURA N ET AL, "Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH., SPRINGER, BERLIN, DE, DE , (19990301), vol. 29, no. 1, doi:10.1007/s005990050057, ISSN 0940-5437, pages 22 - 25, XP002558875
OPPOSITION- NAKAMURA N et al., "Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty add concentrations in patients with hyperlipidemia", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, SPRINGER, BERLIN, DE, (19990301), vol. 29, no. 1, ISSN 0940-5437, pages 22 - 25, XP002558875
OPPOSITION- for the JELIS Investigators, Japan ; Saito, Y. ; Yokoyama, M. ; Origasa, H. ; Matsuzaki, M. ; Matsuzawa, Y. ; Ishikawa, Y. ; Oikawa, S. ; Sasaki, J. ; Hishida, H. ; Itakura, H. ; Kita, T. ; Kitabatake, A. ; Nakaya, N. ; Sakata, T. ; Shimada, K. ; Shirato, K., "Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)", Atherosclerosis, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20080901), vol. 200, no. 1, doi:10.1016/j.atherosclerosis.2008.06.003, ISSN 0021-9150, pages 135 - 140, XP024521515
OPPOSITION- SAITO, Y. et al., "Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS", Atherosclerosis, (20080000), vol. 200, no. 1, doi:10.1016/j.atherosclerosis.2008.06.003, pages 135 - 140, XP024521515
OPPOSITION- Y. SAITO et al., "Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS", Atherosclerosis, (20080000), vol. 200, no. 1, doi:10.1016/j.atherosclerosis.2008.06.003, pages 135 - 140, XP024521515
OPPOSITION- FOR THE JAPAN EPA LIPID INTERVENTION STUDY (JELIS) INVESTIGATORS YOKOYAMA et al., "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open- label, blinded endpoint analysis", THE LANCET, LANCET LIMITED, LONDON, GB, (20070330), vol. 369, ISSN 0140-6736, pages 1090 - 1098, XP022009572
OPPOSITION- for the Japan EPA lipid intervention study (JELIS) Investigators Yokoyama, M. Origasa, H. Matsuzaki, M. Matsuzawa, Y. Saito, Y. Ishikawa, Y. Oikawa, S. Sasaki, J. Hishida, H. Itakura, H. Kita, T. Kitabatake, A. Nakaya, N. Sakata, T. Shimada, K. Shirato, K., "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20070330), vol. 369, no. 9567, doi:10.1016/S0140-6736(07)60527-3, ISSN 0140-6736, pages 1090 - 1098, XP022009572
OPPOSITION- YOKOYAMA et al., "Effects of eicosapentaenoic acid on major coronary events in hypercholesteroiaemic patients (JELIS): a randomised open- label, blinded endpoint analysis", THE LANCET, LONDON, GB, (20070330), vol. 369, no. 9567, ISSN 0140-6736, pages 1090 - 1098, XP022009572
OPPOSITION- Bhatt Deepak L, "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia", N Engl J Mred, doi:10.1056/NEJMoa1812792, (2018), URL: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812792?articleTools=true, XP055673350
OPPOSITION- BHATT, D. L. et al., "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia", N Engl J Med, (20190103), vol. 380, pages 11 - 22, XP055673350
OPPOSITION- Deepak L Bhatt, "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia", doi:10.1056/NEJMoa1812792, (20190103), URL: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812792?articleTools=true, (20200303), XP055673350
OPPOSITION- Durrington P N, Bhatnagar D, Mackness M I, Morgan J, Julier K, Khan M A, France M., "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia", HEART, BMJ, LONDON,, GB, GB , (20010501), vol. 85, no. 5, doi:10.1136/heart.85.5.544 , ISSN 1355-6037, pages 544 - 548, XP002685560
OPPOSITION- DURRINGTON, P.N. et al., "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia", HEART, (20010000), vol. 85, pages 544 - 548, XP002685560
OPPOSITION- K. TANAKA et al., "Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients", Stroke, (20080000), vol. 39, no. 7, doi:10.1161/STROKEAHA.107.509455, pages 3052 - 2058, XP055069541
OPPOSITION- K. Tanaka, Ishikawa Y., Yokoyama M., Origasa H., Matsuzaki M., Saito Y., Matsuzawa Y., Sasaki J., Oikawa S., Hishida H., Itakura H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., Shirato K., "Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial", Stroke, (20080701), vol. 39, no. 7, doi:10.1161/STROKEAHA.107.509455, ISSN 00392499, pages 2052 - 2058, XP055069541
OPPOSITION- TANAKA et al., "Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients", Stroke, (20080000), vol. 39, no. 7, doi:10.1161/STROKEAHA.107.509455, pages 2052 - 2058, XP055069541
SEARCH- RAMBJOR G S ET AL, "EICOSAPENTAENOIC ACID IS PRIMARILY RESPONSIBLE FOR HYPOTRIGLYCERIDEMIC EFFECT OF FISH OIL IN HUMANS", LIPIDS, SPRINGER, US, (19960101), vol. 31, no. 3, SUPPL, doi:10.1007/BF02637050, ISSN 0024-4201, pages S45 - S49, XP000614874 [I] 1-15 * the whole document *
SEARCH- NAKAMURA N ET AL, "Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, SPRINGER, BERLIN, DE, (19990301), vol. 29, no. 1, doi:10.1007/S005990050057, ISSN 0940-5437, pages 22 - 25, XP002558875 [I] 1-15 * the whole document *
SEARCH- FOR THE JAPAN EPA LIPID INTERVENTION STUDY (JELIS) INVESTIGATORS YOKOYAMA ET AL, "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis", THE LANCET, LANCET LIMITED. LONDON, GB, (20070330), vol. 369, no. 9567, doi:10.1016/S0140-6736(07)60527-3, ISSN 0140-6736, pages 1090 - 1098, XP022009572 [I] 1-15 * the whole document *
SEARCH- DURRINGTON, P.N. ET AL., "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia", HEART, (2001), vol. 85, pages 544 - 548, XP002685560 [X] 1,7-14 * the whole document * [I] 1-15

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents